Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 5

REGENERON PHARMACEUTICALS INC

Form 5

Common

Stock

Â

Â

12/20/2016

12/20/2016

February 10, 2017

OMB APPROVAL FORM 5 **OMB** UNITED STATES SECURITIES AND EXCHANGE COMMISSION 3235-0362 Number: Washington, D.C. 20549 Check this box if January 31, Expires: no longer subject 2005 to Section 16. Estimated average ANNUAL STATEMENT OF CHANGES IN BENEFICIAL Form 4 or Form burden hours per 5 obligations OWNERSHIP OF SECURITIES response... 1.0 may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, 1(b). Form 3 Holdings Section 17(a) of the Public Utility Holding Company Act of 1935 or Section Reported 30(h) of the Investment Company Act of 1940 Form 4 Transactions Reported 1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading 5. Relationship of Reporting Person(s) to Issuer YANCOPOULOS GEORGE Symbol REGENERON (Check all applicable) PHARMACEUTICALS INC [REGN] _X_ Director 10% Owner _X__ Officer (give title Other (specify (First) (Middle) 3. Statement for Issuer's Fiscal Year Ended (Last) below) below) (Month/Day/Year) President & CSO 12/31/2016 777 OLD SAW MILL RIVER **ROAD** 4. If Amendment, Date Original (Street) 6. Individual or Joint/Group Reporting Filed(Month/Day/Year) (check applicable line) TARRYTOWN, NYÂ 10591 _X_ Form Filed by One Reporting Person Form Filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of Transaction Form: Direct Indirect Security (Month/Day/Year) Execution Date, if Acquired (A) or Securities (Instr. 3) Code Disposed of (D) Beneficially (D) or Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned at end Indirect (I) Ownership of Issuer's (Instr. 4) (Instr. 4) (A) Fiscal Year or (Instr. 3 and 4) Amount (D) Price Common Â 12/20/2016 G 1.105 D \$0 66,871 Ι by Trust Stock Common 12/20/2016 Â G 1,071 D \$0 65,800 I by Trust Stock

670

536

D

D

\$0

\$0

65,130

64,594

G

G

by Trust

by Trust

Ι

I

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 5

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			Persons who respond to the collection of information contained in this form are not required to respond unless						SEC 2270 (9-02)
Common Stock	Â	Â	Â	Â	Â	Â	5,676	I	By 401(k) Plan
Common Stock	Â	Â	Â	Â	Â	Â	500,000	I	by GRAT
Common Stock	Â	Â	Â	Â	Â	Â	591,348	D	Â
Common Stock	12/20/2016	Â	G	536	D	\$0	64,058	I	by Trust
Common Stock									

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

the form displays a currently valid OMB control number.

O E Is Fi

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ant of rlying	8. Price of Derivative Security (Instr. 5)
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships					
. 0	Director	10% Owner	Officer	Other		
YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	ÂX	Â	President & CSO	Â		

Signatures

/s/**George D. Yancopoulos	02/10/2017		
**Signature of Reporting	Date		

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 5

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. nter"> D Stock Appreciation Right \$ 28.911/03/2017 M 91502/25/201402/25/2020 Common Stock 915 \$ 0 1,830 D Stock Appreciation Right \$ 31.3511/03/2017 M 79003/02/201303/02/2019 Common Stock 790 \$ 0 0 D

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

PRATT KEITH E 5700 LAS POSITAS ROAD LIVERMORE, CA 94551

Executive VP and CFO

Signatures

Kay Dashner, POA for Keith Pratt 11/06/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.